2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)thiophene CAS 1030825-20-7 Kemurnian ≥98,0% (HPLC)

Katrangan singkat:

2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)tiofen

CAS: 1030825-20-7

Penampilan: Bubuk Putih utawa Putih

Kemurnian: ≥98,0% (HPLC)

Intermediate of API (CAS: 842133-18-0) ing perawatan Diabetes Mellitus Tipe 2

Inquiry: alvin@ruifuchem.com

Kirimi email kanggo kita

Detail Produk

Produk sing gegandhengan

Tag produk

katrangan:

Produsen Pasokan Intermediet sing gegandhengan:
4-Asam Fluorofenilboronat CAS: 1765-93-1
2-(4-Fluorophenyl)thiophene CAS: 58861-48-6
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS: 32384-65-9
5-Iodo-2-Asam Metilbenzoat CAS 54811-38-0
2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)tiofen CAS: 1030825-20-7
2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)metil]tiofen CAS: 898566-17-1
CAS: 842133-18-0
CAS: 928672-86-0

Sifat Kimia:

Jeneng Kimia	2-(5-Bromo-2-Methylbenzyl)-5-(4-Fluorophenyl)tiofen
Nomer CAS	1030825-20-7
Nomer CAT	RF-PI234
Status Simpenan	Ing Stok, Skala Produksi Nganti Atusan Kilogram
Formula Molekul	C18H14BrFS
Bobot Molekul	361.27
Titik Lebur	103 ℃
Kapadhetan	1.388
Merk	Kimia Ruifu

Spesifikasi:

Item	Spesifikasi
Penampilan	Bubuk Putih utawa Off-White
Kemurnian / Metode Analisis	≥98,0% (HPLC)
Mundhut ing Pangatusan	≤1,00%
Sisa ing ignition	≤0,50%
Logam abot	≤20ppm
Standar Tes	Standar Perusahaan
Panggunaan	Penengah API (CAS: 842133-18-0)

Paket & Panyimpenan:

Paket: Botol, tas Aluminium foil, 25kg / Drum Karton, utawa miturut kabutuhan pelanggan

Kondisi panyimpenan:Simpen ing wadhah sing disegel ing papan sing adhem lan garing;Nglindhungi saka cahya & Kelembapan

Kaluwihan:

FAQ:

Aplikasi:

Shanghai Ruifu Chemical Co., Ltd. minangka produsen lan supplier 2-(5-Bromo-2-Methylbenzyl) -5-(4-Fluorophenyl)thiophene (CAS: 1030825-20-7) kanthi kualitas dhuwur.Ikuminangka penengah biasane ing sintesis API (CAS: 461432-26-8).API (CAS: 461432-26-8) minangka obat antidiabetik anyar sing dikembangake bebarengan dening Bristol-Myers Squibb lan AstraZeneca, sing disetujoni dening European Medicines Agency (EMA) tanggal 12 November 2012. Iki uga minangka inhibitor SGLT2 pisanan sing disetujoni kanggo perawatan diabetes jinis II, minangka pilihan penting kanggo perawatan diabetes, lan digunakake kanggo nambah kontrol glikemik minangka tambahan kanggo diet lan olahraga kanggo wong diwasa kanthi diabetes tipe II.